Wolfgang Schuh
University of Erlangen-Nuremberg
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Wolfgang Schuh.
Journal of Experimental Medicine | 2009
Daniel Trageser; Ilaria Iacobucci; Rahul Nahar; Cihangir Duy; Gregor von Levetzow; Lars Klemm; Eugene Park; Wolfgang Schuh; Tanja A. Gruber; Sebastian Herzog; Yong-Mi Kim; Wolf-Karsten Hofmann; Aihong Li; Clelia Tiziana Storlazzi; Hans-Martin Jäck; John Groffen; Giovanni Martinelli; Nora Heisterkamp; Hassan Jumaa; Markus Müschen
B cell lineage acute lymphoblastic leukemia (ALL) arises in virtually all cases from B cell precursors that are arrested at pre–B cell receptor–dependent stages. The Philadelphia chromosome–positive (Ph+) subtype of ALL accounts for 25–30% of cases of adult ALL, has the most unfavorable clinical outcome among all ALL subtypes and is defined by the oncogenic BCR-ABL1 kinase and deletions of the IKAROS gene in >80% of cases. Here, we demonstrate that the pre–B cell receptor functions as a tumor suppressor upstream of IKAROS through induction of cell cycle arrest in Ph+ ALL cells. Pre–B cell receptor–mediated cell cycle arrest in Ph+ ALL cells critically depends on IKAROS function, and is reversed by coexpression of the dominant-negative IKAROS splice variant IK6. IKAROS also promotes tumor suppression through cooperation with downstream molecules of the pre–B cell receptor signaling pathway, even if expression of the pre–B cell receptor itself is compromised. In this case, IKAROS redirects oncogenic BCR-ABL1 tyrosine kinase signaling from SRC kinase-activation to SLP65, which functions as a critical tumor suppressor downstream of the pre–B cell receptor. These findings provide a rationale for the surprisingly high frequency of IKAROS deletions in Ph+ ALL and identify IKAROS-mediated cell cycle exit as the endpoint of an emerging pathway of pre–B cell receptor–mediated tumor suppression.
Journal of Experimental Medicine | 2010
Cihangir Duy; J. Jessica Yu; Rahul Nahar; Srividya Swaminathan; Soo Mi Kweon; Jose M. Polo; Ester Valls; Lars Klemm; Seyedmehdi Shojaee; Leandro Cerchietti; Wolfgang Schuh; Hans-Martin Jäck; Christian Hurtz; Parham Ramezani-Rad; Sebastian Herzog; Hassan Jumaa; H. Phillip Koeffler; Ignacio Moreno de Alborán; Ari Melnick; B. Hilda Ye; Markus Müschen
BCL6 protects germinal center (GC) B cells against DNA damage–induced apoptosis during somatic hypermutation and class-switch recombination. Although expression of BCL6 was not found in early IL-7–dependent B cell precursors, we report that IL-7Rα–Stat5 signaling negatively regulates BCL6. Upon productive VH-DJH gene rearrangement and expression of a μ heavy chain, however, activation of pre–B cell receptor signaling strongly induces BCL6 expression, whereas IL-7Rα–Stat5 signaling is attenuated. At the transition from IL-7–dependent to –independent stages of B cell development, BCL6 is activated, reaches expression levels resembling those in GC B cells, and protects pre–B cells from DNA damage–induced apoptosis during immunoglobulin (Ig) light chain gene recombination. In the absence of BCL6, DNA breaks during Ig light chain gene rearrangement lead to excessive up-regulation of Arf and p53. As a consequence, the pool of new bone marrow immature B cells is markedly reduced in size and clonal diversity. We conclude that negative regulation of Arf by BCL6 is required for pre–B cell self-renewal and the formation of a diverse polyclonal B cell repertoire.
Journal of Experimental Medicine | 2015
Jan P. Weber; Franziska Fuhrmann; Randi K. Feist; Annette Lahmann; Maysun S. Al Baz; Lea-Jean Gentz; Dana Vu Van; Hans W. Mages; Claudia Haftmann; René Riedel; Joachim R. Grün; Wolfgang Schuh; Richard A. Kroczek; Andreas Radbruch; Mir-Farzin Mashreghi; Andreas Hutloff
ICOS signaling is required for inhibition of the transcription factor Klf2, which controls expression of genes expressed by follicular T helper (Tfh) cells. When ICOS signaling is blocked, Tfh cells lose expression of characteristic Tfh genes and revert to an effector phenotype, resulting in disruption of the germinal center response.
Nature Immunology | 2017
René Pfeifle; Tobias Rothe; Natacha Ipseiz; Hans Ulrich Scherer; Stephan Culemann; Ulrike Harre; Jochen A. Ackermann; Martina Seefried; Arnd Kleyer; Stefan Uderhardt; Benjamin Haugg; Axel J. Hueber; Patrick Daum; Gordon F. Heidkamp; Changrong Ge; Sybille Böhm; Anja Lux; Wolfgang Schuh; Iryna Magorivska; Kutty Selva Nandakumar; Erik Lönnblom; Christoph Becker; Diana Dudziak; Manfred Wuhrer; Yoann Rombouts; Carolien A. M. Koeleman; René E. M. Toes; Thomas H. Winkler; Rikard Holmdahl; Martin J. Herrmann
The checkpoints and mechanisms that contribute to autoantibody-driven disease are as yet incompletely understood. Here we identified the axis of interleukin 23 (IL-23) and the TH17 subset of helper T cells as a decisive factor that controlled the intrinsic inflammatory activity of autoantibodies and triggered the clinical onset of autoimmune arthritis. By instructing B cells in an IL-22- and IL-21-dependent manner, TH17 cells regulated the expression of β-galactoside α2,6-sialyltransferase 1 in newly differentiating antibody-producing cells and determined the glycosylation profile and activity of immunoglobulin G (IgG) produced by the plasma cells that subsequently emerged. Asymptomatic humans with rheumatoid arthritis (RA)-specific autoantibodies showed identical changes in the activity and glycosylation of autoreactive IgG antibodies before shifting to the inflammatory phase of RA; thus, our results identify an IL-23–TH17 cell–dependent pathway that controls autoantibody activity and unmasks a preexisting breach in immunotolerance.
Journal of Immunology | 2003
Wolfgang Schuh; Silke Meister; Edith Roth; Hans-Martin Jäck
Pre-B cell receptor (pre-BCR) signals are essential for pro-B cells to mature efficiently into pre-B cells. The pre-BCR is an Ig-like transmembrane complex that is assembled from two μH chains (μHC) and two surrogate L chains consisting of the non-covalently associated polypeptides VpreB and λ5. In λ5−/− mice, pro-B cell maturation is impaired, but not completely blocked, implying that a μHC induces differentiation signals in the absence of λ5. Using a mouse model, in which transgenic μHC expression can be controlled by tetracycline, we show that in the absence of λ5, the transgenic μHC promotes in vivo differentiation of pro-B cells, induces IL-7-dependent cell growth, and is expressed on the surface of pre-B cells. Our findings not only show that an incomplete pre-BCR can initiate signals, but also challenge the paradigm that an IgHC must associate with an IgLC or a SLC to gain transport and signaling competency.
Proceedings of the National Academy of Sciences of the United States of America | 2011
Rebecca Winkelmann; Lena Sandrock; Martina Porstner; Edith Roth; Martina Mathews; Elias Hobeika; Michael Reth; Mark L. Kahn; Wolfgang Schuh; Hans-Martin Jäck
Krüppel-like factor 2 (KLF2) controls T lymphocyte egress from lymphoid organs by regulating sphingosin-1 phosphate receptor 1 (S1Pr1). Here we show that this is not the case for B cells. Instead, KLF2 controls homeostasis of B cells in peripheral lymphatic organs and homing of plasma cells to the bone marrow, presumably by controlling the expression of β7-integrin. In mice with a B cell-specific deletion of KLF2, S1Pr1 expression on B cells was only slightly affected. Accordingly, all splenic B cell subsets including B1 cells were present, but their numbers were increased with a clear bias for marginal zone (MZ) B cells. In contrast, fewer peyers patches harboring fewer B cells were found, and fewer B1 cells in the peritoneal cavity as well as recirculating B cells in the bone marrow were detected. Upon thymus-dependent immunization, IgG titers were diminished, and antigen-specific plasma cells were absent in the bone marrow, although numbers of antigen-specific splenic plasmablasts were normal. KLF2 plays also a role in determining the identity of follicular B cells, as KLF2-deficient follicular B cells showed calcium responses similar to those of MZ B cells and failed to down-regulate MZ B cell signature genes, such as CD21 and CXCR7.
Cell Death & Differentiation | 2007
Athanasia Avramidou; Kroczek C; Charles H. Lang; Wolfgang Schuh; Hans-Martin Jäck; Dirk Mielenz
B-cell receptor (BCR) signals are essential for B-cell differentiation, homeostasis and negative selection, which are regulated by the strength and quality of BCR signals. Recently, we identified a new adaptor protein, Swiprosin-1, in lipid rafts of B-cell lines that undergo apoptosis after BCR stimulation. During murine B-cell development, Swiprosin-1 exhibited highest expression in immature B cells of the bone marrow, but was also expressed in resting and activated splenic B cells and in non-lymphoid tissue, especially in the brain. Ectopic expression of Swiprosin-1 in the immature murine B-cell line WEHI231 enhanced spontaneous and BCR-induced apoptosis. In contrast, short hairpin RNA (shRNA)-mediated downregulation of Swiprosin-1 impaired specifically spontaneous and BCR-elicited apoptosis, but not BCR-induced G1 cell cycle arrest and upregulation of the cell cycle inhibitor p27Kip1. In accordance, Swiprosin-1 abundance regulated net cell growth of WEHI231 cell populations through reciprocal regulation of Bcl-xL, but not Bim, thereby controlling spontaneous apoptosis. Swiprosin-1-enhanced apoptosis was blocked through nuclear factor κB-activating stimuli, namely B-cell-activating factor of the TNF family, anti-CD40 and lipopolysaccharide (LPS). This correlated with enhanced BCR-induced IκB-α phosphorylation and degradation in cells expressing a Swiprosin-1-specific shRNA. Finally, ectopic Swiprosin-1 expression enhanced BCR-induced cell death in primary, LPS-stimulated splenic B cells. Hence, Swiprosin-1 may regulate lifespan and BCR signaling thresholds in immature B cells.
Journal of Gene Medicine | 2006
Christel Krueger; Christina Danke; Klaus Pfleiderer; Wolfgang Schuh; Hans-Martin Jäck; Susanne Lochner; Peter Gmeiner; Wolfgang Hillen; Christian Berens
The amount of a particular protein, and not just its presence or absence, frequently determines the outcome of a developmental process or disease progression. These dosage effects can be studied by conditionally expressing such proteins at different levels. With typical gene regulation systems like the Tet‐On system, intermediate expression levels can be obtained by varying the effector concentration. However, this strategy is limited to situations in which these concentrations can be precisely controlled and, thus, not suited for animal models or gene therapy approaches. Here, we present a Tet transregulator setup that allows establishment of four levels of promoter activity largely independent of effector concentration.
Blood | 2016
Julia Herglotz; Ludmilla Unrau; Friderike Hauschildt; Meike Fischer; Neele Kriebitzsch; Malik Alawi; Daniela Indenbirken; Michael Spohn; Ursula Müller; Marion Ziegler; Wolfgang Schuh; Hans-Martin Jäck; Carol Stocking
The sequential activation of distinct developmental gene networks governs the ultimate identity of a cell, but the mechanisms involved in initiating downstream programs are incompletely understood. The pre-B-cell receptor (pre-BCR) is an important checkpoint of B-cell development and is essential for a pre-B cell to traverse into an immature B cell. Here, we show that activation of myocyte enhancer factor 2 (Mef2) transcription factors (TFs) by the pre-BCR is necessary for initiating the subsequent genetic network. We demonstrate that B-cell development is blocked at the pre-B-cell stage in mice deficient for Mef2c and Mef2d TFs and that pre-BCR signaling enhances the transcriptional activity of Mef2c/d through phosphorylation by the Erk5 mitogen-activating kinase. This activation is instrumental in inducing Krüppel-like factor 2 and several immediate early genes of the AP1 and Egr family. Finally, we show that Mef2 proteins cooperate with the products of their target genes (Irf4 and Egr2) to induce secondary waves of transcriptional regulation. Our findings uncover a novel role for Mef2c/d in coordinating the transcriptional network that promotes early B-cell development.
Immunology and Cell Biology | 2013
Phillip D. Fromm; Iain Comerford; Ervin E. Kara; Jennifer L. Bannan; Wolfgang Schuh; Charani Ranasinghe; David M. Tarlinton; Thomas H. Winkler; Heinrich Körner
The CC‐chemokine receptor 6 (CCR6) is expressed constitutively at an intermediate level on naïve B cells and is upregulated after activation on pregerminal center (GC) B cells. We hypothesized that it could be involved in the events leading to GC reaction and high‐affinity antibody production, and therefore investigated the potential role of CCR6 in B‐cell differentiation in vivo. After antigenic challenge of CCR6−/− mice with the T‐cell‐dependent antigen nitrophenyl‐keyhole limpet hemocyanin (NP‐KLH), GC B‐cell development was found to be accelerated and the number of GC had increased significantly compared with control mice, but the antibodies produced by CCR6−/− B cells were on average of lower affinity. We conclude from these data that the CCR6/CCL20 axis has an important role in regulating the kinetics and efficiency of the GC reaction.